How Long Does PT-141 Last?
Share
The duration of action and effects of PT-141 (Bremelanotide)
PT-141, marketed under the brand name Vyleesi, is a melanocortin receptor agonist used for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The pharmacokinetics and pharmacodynamics of PT-141 provide insight into its duration of action and effects.
Following subcutaneous administration, PT-141 exhibits rapid absorption with a median time to peak plasma concentration (Tmax) of approximately 1 hour (range: 0.5 - 1.0 hours). The mean plasma concentration (Cmax) and area under the curve (AUC) indicate that the drug reaches therapeutic levels quickly, which is beneficial for its intended use prior to anticipated sexual activity.[1]
The effects of PT-141 typically last for about 8-12 hours. This duration is supported by the pharmacokinetic profile, where the mean terminal half-life of PT-141 is approximately 2.7 hours (range: 1.9–4.0 hours). The transient increase in blood pressure and decrease in heart rate observed post-administration usually resolve within 12 hours. This aligns with the clinical recommendation to not exceed one dose within 24 hours and no more than 8 doses per month.[1]
In terms of therapeutic effects, PT-141 improves sexual desire and reduces distress associated with low sexual desire. Clinical trials have demonstrated significant improvements in these parameters, with the onset of action occurring within 45 minutes to 2 hours post-administration.[2] The effects on sexual desire are sustained for several hours, making PT-141 a suitable option for on-demand use.
Adverse effects such as nausea, flushing, and headache are common but generally mild and transient. Nausea, the most frequently reported side effect, typically lasts for about 2 hours after dosing but can persist longer in some patients.[1] The transient nature of these side effects further supports the 8-12 hour duration of action for PT-141.
In summary, PT-141 (Bremelanotide) exhibits a rapid onset of action with effects lasting approximately 8-12 hours. This duration is consistent with its pharmacokinetic profile and clinical observations, making it an effective on-demand treatment for HSDD in premenopausal women.
1. Vyleesi. FDA Drug Label. Food and Drug Administration Updated date: 2025-01-10
2. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.
Mayer D, Lynch SE. The Annals of Pharmacotherapy. 2020;54(7):684-690. doi:10.1177/1060028019899152.